Role of epigenetic mechanisms in the development of chronic complications of diabetes

Diabetes Research and Clinical Practice

Volumn 105, Issue 2, 2014, Pages 164-175

  Wegner, Malgorzata ^a   Neddermann, Daniel ^b   Piorunska Stolzmann, Maria ^a   Jagodzinski, Pawel P ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chronic complications; Diabetes; Epigenetic; Metabolic memory

Indexed keywords

ANTIDIABETIC AGENT; DNA; DNA METHYLTRANSFERASE; GLUCOSE; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEMETHYLASE; HISTONE METHYLTRANSFERASE; INSULIN; MESSENGER RNA; MICRORNA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; TRANSFORMING GROWTH FACTOR BETA1; UBIQUITIN PROTEIN LIGASE;

CHRONIC INFLAMMATION; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DNA METHYLATION; DNA MODIFICATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; EPIGENETICS; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE EXPRESSION REGULATION; GLYCEMIC CONTROL; HEART MUSCLE CELL; HISTONE MODIFICATION; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; RETINA CELL; REVIEW; RNA TRANSLATION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

CHRONIC COMPLICATIONS; DIABETES; EPIGENETIC; METABOLIC MEMORY;

DIABETES COMPLICATIONS; EPIGENESIS, GENETIC; HUMANS;

EID: 84906043443     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.03.019     Document Type: Review

References (104)

1. Imam K. Clinical features, diagnostic criteria and pathogenesis of diabetes mellitus. Adv Exp Med Biol 2012, 771:340-355.
2. Villeneuve L.M., Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am J Physiol 2010, 299:14-25.
3. Reddy M.A., Natarajan R. Epigenetic mechanisms in diabetic vascular complications. Cardiovasc Res 2011, 90:421-429.
4. King G.L., Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 1999, 25:255-270.
5. Nokoff N., Rewers M. Pathogenesis of type 1 diabetes: lessons from natural history studies of high-risk individuals. Ann NY Acad Sci 2013, 1281:1-15.
6. Pezzolesi M.G., Krolewski A.S. The genetic risk of kidney disease in type 2 diabetes. Med Clin North Am 2013, 97:91-107.
7. Atkinson M.A. The pathogenesis and natural history of type 1 diabetes. Cold Spring Harb Perspect Med 2012, 2(11):1-18.
8. Karaguzel G., Ozer S., Akcurin S., Turkkahraman D., Bircan I. Type 1 diabetes-related epidemiological, clinical and laboratory findings. An evaluation with special regard to autoimmunity in children. Saudi Med J 2007, 28:584-589.
9. Gupta D., Krueger C.B., Lastra G. Over-nutrition, obesity and insulin resistance in the development of β-cell dysfunction. Curr Diabetes Rev 2012, 8:76-83.
10. MacFarlane A.J., Strom A., Scott F.W. Epigenetics: deciphering how environmental factors may modify autoimmune type 1 diabetes. Mamm Genome 2009, 20:624-632.
11. Keating S., El-Osta A. Epigenetic changes in diabetes. Clin Genet 2013, 84:1-10.
12. Pirola L., Balcerczyk A., Okabe J., El-Osta A. Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol 2010, 6:665-675.
13. Villeneuve L.M., Reddy M.A., Natarajan R. Epigenetics: deciphering its role in diabetes and its chronic complications. Clin Exp Pharmacol Physiol 2011, 38:451-459.
14. Miao F., Gonzalo I.G., Lanting L., Natarajan R. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem 2004, 279:18091-18097.
15. Ha T.-Y. MicroRNAs in human diseases: from cancer to cardiovascular disease. Immune Netw 2011, 11:135-154.
16. Waddington C.H. Der epigenotypus. Endeavour 1942, 1:18-20.
17. Holliday R. The inheritance of epigenetic defects. Science 1987, 238:163-170.
18. Meagher R.B., Müssar K.J. The influence of DNA sequence on epigenome induced pathologies. Epigenetics Chromatin 2012, 5:11.
19. Fraga M.F., Ballestar E., Paz M.F., Ropero S., Setien F., Ballestar M.L., et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005, 102:10604-10609.
20. James L.I., Frye S.V. Targeting chromatin readers. Clin Pharmacol Ther 2013, 93:312-314.
21. Grewal S.I., Jia S. Heterochromatin revisited. Nat Rev Genet 2007, 8:35-46.
22. Bush K.M., Yuen B.T., Barrilleaux B.L., Riggs J.W., O'Geen H., Cotterman R.F., et al. Endogenous mammalian histone H3.3 exhibits chromatin-related functions during development. Epigenetics Chromatin 2013, 9:7.
23. Musselman C., Lalonde M.E., Côté J., Kutateladze T.G. Perceiving the epigenetic landscape through histone readers. Nat Struct Mol Biol 2012, 19:1218-1227.
24. Jaenisch R., Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003, 33:245-254.
25. Nightingale K.P., O'Neill L.P., Turner B.M. Histone modifications: signaling receptors and potential elements of a heritable epigenetic code. Curr Opin Genet Dev 2006, 16:125-136.
26. Fetita L.S., Sobngwi E., Serradas P., Calvo F., Gautier J.F. Consequences of fetal exposure to maternal diabetes in offspring. J Clin Endocrinol Metab 2006, 91:3718-3724.
27. Allis C.D., Jenuwein T., Reinberg D. Epigenetics 2007, 502. Inglis, John, Cold Spring Habor.
28. Wang Z., Zang C., Rosenfeld J.A., Schones D.E., Barski A., Cuddapah S. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 2008, 40:897-903.
29. Cooper M.E., El-Osta A. Epigenetics: mechanisms and implications for diabetic complications. Circ Res 2010, 107:1403-1413.
30. Upadhyay A.K., Cheng X. Dynamics of histone lysine methylation: structures of methyl writers and erasers. Prog Drug Res 2011, 67:107-124.
31. Turner B. Decoding the nucleosome. Cell 1993, 75:5-8.
32. Li E. Chromatin modification and epigenetic reprogramming in mammalian development: nature reviews. Genetics 2002, 3:662-673.
33. Kouzarides T. Chromatin modifications and their function. Cell 2007, 23:693-705.
34. Li B., Carey M., Workman J.L. The role of chromatin during transcription. Cell 2007, 23:707-719.
35. Butler J., Koutelou E., Schibler A., Dent S. Histone-modifying enzymes: regulators of developmental decisions and drivers of human disease. Epigenomics 2012, 4:163-177.
36. Allfrey V., Faulkner R., Mirsky A. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci USA 1964, 51:786-794.
37. Ho E., Clarke J.D., Dashwood R.H. Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. J Nutr 2009, 139:2393-2396.
38. Avvakumov N., Côté J. The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene 2007, 26:5395-5407.
39. Liang G., Klose R.J., Gardner K.E., Zhang Y. Yeast Jhd2p is a histone H3 Lys4 trimethyldemethylase. Nat Struct Mol Biol 2007, 14:243-245.
40. Gordon C.A., Hartono S.R., Chédin F. Inactive DNMT3B splice variants modulate de novo DNA methylation. PLoS ONE 2013, 19:e69486.
41. Shahbazian M.D., Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 2007, 76:75-100.
42. Koh K.P., Rao A. DNA methylation and methylcytosine oxidation in cell fate decisions. Curr Opin Chem Biol 2013, 25:152-161.
43. Martin C., Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 2005, 6:838-849.
44. Barski A., Cuddapah S., Cui K., Roh T.Y., Schones D.E., Wang Z., et al. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129:823-837.
45. Cedar H., Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009, 10:295-304.
46. Jin B., Robertson K.D. DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol 2013, 754:3-29.
47. Ooi S.K.T., Bestor T.H. The colorful history of active DNA demethylation. Cell 2008, 133:1145-1148.
48. Walsh C.P., Bestor T.H. Cytosine methylation and mammalian development. Genes Dev 1999, 13:26-34.
49. Liang G., Chan M., Tomigahara Y. Cooper activity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol 2002, 2:480-491.
50. Straussman R., Nejman D., Roberts D., Steinfeld I., Blum B., Benvenisty N., et al. Developmental programming of CpG island methylation profiles in the human genome. Nat Struct Mol Biol 2009, 16:564-571.
51. Fan S., Zhang X. CpG island methylation pattern in different human tissues and its correlation with gene expression. Biochem Biophys Res Commun 2009, 383:421-425.
52. Lister R., Pelizzola M., Dowen R.H., Hawkins R.D., Hon G., Tonti-Filippini J., et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009, 462:315-322.
53. Laird P.W. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003, 3:253-266.
54. El Gazzar M., McCall C.E. MicroRNAs regulatory networks in myeloid lineage development and differentiation: regulators of the regulators. Immunol Cell Biol 2012, 90:587-593.
55. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5(7):522-523.
56. Bartel D. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
57. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002, 16:6-21.
58. Feinberg A., Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92.
59. Khalil A.M., Rinn J.L. RNA-protein interactions in human health and disease. Cell Dev Biol 2011, 22:359-365.
60. Lawless M.W., O'Byrne K.J., Gray S.G. Histone deacetylase inhibitors target diabetes via chromatin remodeling or as chemical chaperones?. Curr Diabetes Rev 2009, 5(3):201-209.
61. DCCT/EDIC Writing Team: effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002, 287:2563-2569.
62. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
63. Chalmers J., Cooper M.E. UKPDS and the legacy effect. N Engl J Med 2008, 359:1618-1620.
64. Intine R.V., Sarras M.P. Metabolic memory and chronic diabetes complications: potential role for epigenetic mechanisms. Curr Diab Rep 2012, 12:551-559.
65. Miao F., Wu X., Zhang L., Yuan Y.C., Riggs A.D., Natarajan R. Genome-wide analysis of histone lysine methylation variations caused by diabetic conditions in human monocytes. J Biol Chem 2007, 282:13854-13863.
66. Kim H.J., Kim S.H., Yun J.M. Fisetin inhibits hyperglycemia-induced proinflammatory cytokine production by epigenetic mechanisms. Evid Based Complement Alternat Med 2012, 2012:639469.
67. Miao F., Smith D.D., Zhang L., Min A., Feng W., Natarajan R. Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. Diabetes 2008, 57:3189-3198.
68. Reddy M.A., Villeneuve L.M., Wang M., Lanting L., Natarajan R. Role of the lysine-specific demethylase 1 in the proinflammatory phenotype of vascular smooth muscle cells of diabetic mice. Circ Res 2008, 103:615-623.
69. Brasacchio D., Okabe J., Tikellis C., Balcerczyk A., George P., Baker E.K., et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 2009, 58:1229-1236.
70. Villeneuve L.M., Reddy M.A., Lanting L.L., Wang M., Meng L., Natarajan R. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci USA 2008, 105:9047-9052.
71. Okabe J., Orlowski C., Balcerczyk A., Tikellis C., Thomas M.C., Cooper M.E., et al. Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circ Res 2012, 110:1067-1076.
72. Yu X.Y., Geng Y.J., Liang J.L., Zhang S., Lei H.P., Zhong S.L., et al. High levels of glucose induce metabolic memory in cardiomyocyte via epigenetic histone H3 lysine 9 methylation. Mol Biol Rep 2012, 39:8891-8898.
73. Zhong Q., Kowluru R.A. Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. Diabetes 2011, 60:1304-1313.
74. Zhong Q., Kowluru R.A. Epigenetic modification of sod2 in the development of diabetic retinopathy and in the metabolic memory: role of histone methylation. Invest Ophthalmol Vis Sci 2013, 54:244-250.
75. Zhong Q., Kowluru R.A. Role of histone acetylation in the development of diabetic retinopathy and the metabolic memory phenomenon. J Cell Biochem 2010, 110:1306-1313.
76. Roy S., Sala R., Cagliero E., Lorenzi M. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci USA 1990, 87:404-408.
77. Brownlee M. The pathobiology of diabetes complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
78. Stitt A.W. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol 2003, 1:95-108.
79. Sun G., Reddy M.A., Yuan H., Lanting L., Kato M., Natarajan R. Epigenetic histone methylation modulates fibrotic gene expression. J Am Soc Nephrol 2010, 21:2069-2080.
80. Miao F., Chen Z., Genuth S., Paterson A., Zhang L., Wu X., et al. Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes 2014, [Epub ahead of print].
81. Feng B., Ruiz M.A., Chakrabarti S. Oxidative-stress-induced epigenetic changes in chronic diabetic complications. Can J Physiol Pharmacol 2013, 91:213-220.
82. Kiss L., Szabó C. The pathogenesis of diabetic complications: the role of DNA injury and poly(ADP-ribose) polymerase activation in peroxynitrite-mediated cytotoxicity. Mem Inst Oswaldo Cruz 2005, 100(1):29-37.
83. El-Osta A., Brasacchio D., Yao D., Pocai A., Jones P.L., Roeder R.G., et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. Exp Med 2008, 205:2409-2417.
84. Reddy M.A., Sahar S., Villeneuve L.M., Lanting L., Natarajan R. Role of Src tyrosine kinase in the atherogenic effects of the 12/15-lipoxygenase pathway in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2009, 29:387-393.
85. Nitert M.D., Dayeh T., Volkov P., Elgzyri T., Hall E., Nilsson E., et al. Impact of an exercise intervention on DNA methylation in skeletal muscle from first-degree relatives of patients with type 2 diabetes. Diabetes 2012, 61:3322-3332.
86. Bell C.G., Teschendorff A.E., Rakyan V.K., Maxwell A.P., Beck S., Savage D.A. Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Med. Genomics. 2010, 3:33.
87. Poirier L.A., Brown A.T., Fink L.M., Wise C.K., Randolph C.J., Delongchamp R.R., et al. Blood S-adenosylmethionine concentrations and lymphocyte methylenetetrahydrofolatereductase activity in diabetes mellitus and diabetic nephropathy. Metabolism 2001, 50:1014-1018.
88. Williams K.T., Garrow T.A., Schalinske K.L. Type I diabetes leads to tissue-specific DNA hypomethylation in male rats. J Nutr 2008, 138:2064-2069.
89. Williams K.T., Schalinske K.L. Tissue-specific alterations of methyl group metabolism with DNA hypermethylation in the Zucker (type 2) diabetic fatty rat. Diabetes Metab Res Rev 2012, 28:123-131.
90. Tewari S., Zhong Q., Santos J.M., Kowluru R.A. Mitochondria DNA replication and DNA methylation in the metabolic memory associated with continued progression of diabetic retinopathy. Invest Ophthalmol Vis Sci 2012, 53:4881-4888.
91. Alvarez M.L., Distefano J.K. The role of non-coding RNAs in diabetic nephropathy: potential applications as biomarkers for disease development and progression. Diabetes Res Clin Pract 2013, 99:1-11.
92. Long J., Wang Y., Wang W., Chang B.H., Danesh F.R. MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem 2011, 286:11837-11848.
93. Gross I., Morrison D.J., Hyink D.P., Georgas K., English M.A., Mericskay M., et al. The receptor tyrosine kinase regulator Sprouty1 is a target of the tumor suppressor WT1 and important for kidney development. J Biol Chem 2003, 278:41420-41430.
94. Fu Y., Zhang Y., Wang Z., Wang L., Wei X., Zhang B., et al. Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy. Am J Nephrol 2010, 32:581-589.
95. Zhang Z., Peng H., Chen J., Chen X., Han F., Xu X., et al. MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett 2009, 583:2009-2014.
96. Wang Q., Wang Y., Minto A.W., Wang J., Shi Q., Li X., et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J 2008, 22:4126-4135.
97. Krupa A., Jenkins R., Luo D.D., Lewis A., Phillips A., Fraser D.J. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. Am Soc Nephrol 2010, 21(3):438-447.
98. Wang B., Herman-Edelstein M., Koh P., Burns W., Jandeleit-Dalm K., Watson A., et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-b. Diabetes 2010, 59:1794-1802.
99. Kovacs B., Lumayag S., Cowan C., Xu S. MicroRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 2011, 52:4402-4409.
100. McArthur K., Feng B., Wu Y., Chen S., Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes 2011, 60(4):1314-1323.
101. Shan Z.X., Lin Q.X., Deng C.Y., Zhu J.N., Mai L.P., Liu J.L., et al. miR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes. FEBS Lett 2010, 584:3592-3600.
102. Feng B., Chen S., George B., Feng Q., Chakrabarti S. miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab Res Rev 2010, 26(1):40-49.
103. Shen E., Diao X., Wang X., Chen R., Hu B. MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocytehypertrophy. Am J Pathol 2011, 179:639-650.
104. Zhang C.B., Zhou Q., Shen C.X., Wang C.Q. Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene Spred-1. J Mol Cell Cardiol 2012, 53:64-72.